Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

ACI Worldwide

Lionheart Holdings

Danone SA

Delek US Hlds

Elanco Animal Health Inc

FirstEnergy

Forward Air

Intel

Kohl's

Prudential

Exxon Mobil

Xerox

Poorly managed companies may not be on everyone's radar, but they're top picks for activist investors looking to boost shareholder value.

13 Stocks Activist Investors Are Buying

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics appoints Brent Saunders, Robert Ruffolo, Ph.D., and Robin Steele to its Board of Directors

OcuTerra Strengthens Board of Directors with Three New Key Appointments

Bausch Health Companies' (BHC) CEO Joe Papa on Q1 2021 Results - Earnings Call Transcript

The company's mixed Q1 results are partially to blame.

Why Bausch Health Stock Is Falling Today

Albertsons Companies

Bausch Health and Albertsons offer excellent bang for your buck.

2 Top Value Stocks to Buy in May

Bausch (BHC) delivered earnings and revenue surprises of 10.64% and -2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Beats Q1 Earnings Estimates

Shares of Bausch Health Cos. Inc. were down 2.3% in premarket trading on Tuesday after the company said it faced continued pressure on sales from the COVID-19 pandemic into the first quarter of this year.

Bausch reports a $610 million loss in the first quarter of the year

LAVAL, Quebec, May 4, 2021 /PRNewswire/ --  First-Quarter 2021 Financial Results Revenues of $2.027 Billion GAAP Net Loss of $610 Million Adjusted EBITDA (non-GAAP) 1 of $852 Million GAAP Cash Generated from Operations of $443 Million Company Continues to Make Progress on Planned Separation of Eye Health Business Announces Leadership Team of Bausch + Lomb Now Operates in Five Reportable Segments Reaffirmed 2021 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its first-quarter 2021 financial results. "Bausch Health entered 2021 with strong momentum as our recovery from the COVID-19 pandemic continues.

Bausch Health Companies Inc. Announces First-Quarter 2021 Results

Bausch Health Companies Inc (NYSE: BHC) said in August that it would spin off its eye-care unit and operate it as an independent, publicly traded company. As a standalone company, Bausch + Lomb could be valued at $20 billion to $30 billion, according to Bloomberg Intelligence.

Bausch Health Exploring Potential Divestiture Of Eye Care Units: Bloomberg

In recent years, one of the worst hedge fund trades was Bill Ackman (Trades, Portfolio)'s Valeant (today called Bausch Health Companies Inc. ( BHC , Financial)) debacle.

The Psychological Biases That Drove Bill Ackman's $4 Billion Valeant Loss

LAVAL, Quebec, April 28, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the election of the 13 directors nominated at its 2021 annual meeting of shareholders held on April 27, 2021. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Richard U.

Bausch Health Announces 2021 Annual Meeting of Shareholder Results

LAVAL, QC, April 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the Company is providing a presentation on its business during the Company's Annual Meeting of Shareholders on April 27, 2021. The presentation will be available on the Investor Relations section of the Bausch Health website.

Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation

SOPHIA ANTIPOLIS, France, and LAVAL, Quebec, April 16, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária). VYZULTA is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.1 "The approval of VYZULTA in Brazil marks its tenth regulatory approval.

Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil

Low-Risk Field - Biosimilars have a 95% FDA approval success rate (36/38 cases). Only two Indian frauds did not pass. Big Market - Xbrane developed a biosimilar product to Lucentis (produced by Roche) with annual revenues of USD 3 billion, with a total market size of USD12 billion.

Xbrane Partners With Bausch & Lomb To Enter USD 12 Billion Market

Amphastar Pharma

Dr. Reddy's Labs

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

All Primary and Secondary Endpoints Were Achieved LAVAL, QC and HEIDELBERG, Germany, April 13, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). Dry eye disease is one of the most common ocular surface disorders causing discomfort for millions of Americans, with MGD playing a key role in the development of the disease.1,2 The GOBI trial met both of its co-primary endpoints, including: Change from baseline in total Corneal Fluorescein Staining (tCFS), a measure of assessing damage to the eye, achieved statistical significance at day 15 [p-value = 0.001] (secondary endpoint), with continued results through day 57 (primary endpoint) compared to control [p-value < 0.001], Change from baseline in dryness score achieved statistical significance at day 15 [p-value = 0.009] (secondary endpoint), with continued results through day 57 (primary endpoint) compared to control [p-value < 0.001], as rated on a visual analogue scale (VAS) ranging from 0-100 (0 = no discomfort; 100 = maximum discomfort).

Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction

Aurora Cannabis

AMC Entertainment

Looking for outside-the-box investments in an overvalued market? Here are your best bets.

3 Distressed Stocks for Contrarian Investors to Buy in April

LAVAL, QC, April 9, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its first-quarter 2021 financial results on Tuesday, May 4, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m.

Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4

Proprietary Blend of Five Live Probiotic Strains Shown to Help Reduce Severity and Frequency of Common, Occasional GI Symptoms* Now Rolling out to Major U.S. Retailers LAVAL, QC, April 8, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced the U.S. launch of its novel daily over-the-counter probiotic supplement, ENVIVE™. ENVIVE™ is shown to help reduce the severity and frequency of five occasional gastrointestinal (GI) symptoms - diarrhea, constipation, gas, bloating and discomfort - and help strengthen and protect the digestive system by strengthening the gut barrier.

Bausch Health Launches ENVIVE™ Daily Probiotic Supplement

Bausch Health Companies Inc. said Wednesday it will reduce debt by another $100 million using cash from operations to redeem its outstanding 7.00% senior secured notes due in 2024. The company, the former Valeant, already redeemed $200 million aggregate principal amount of the bonds in March.

Bausch Health to reduce debt by $100 million using cash from operations

New OVD Offers Exceptional Corneal Protection, Visibility During Ophthalmic Surgery LAVAL, QC, April 7, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the U.S. Food and Drug Administration (FDA) has approved ClearVisc™ dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. "The ClearVisc™ dispersive OVD is the latest advancement in Bausch + Lomb's rich pipeline of ophthalmic surgical devices and is representative of our company's ongoing commitment to delivering innovations that fulfill the unmet needs of our customers," said Joe Gordon, U.S. president, Bausch + Lomb.

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device

LAVAL, Quebec, March 31, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that it and certain of its affiliates have entered into a definitive agreement to sell all of their equity interests in Amoun Pharmaceutical Company S.A.E. ("Amoun") to Abu-Dhabi based ADQ (the "Purchaser"), one of the region's largest holding companies, for total gross consideration of approximately U.S. $740 million (including the assignment to the Purchaser of an intercompany loan granted by Bausch Health to Amoun), subject to certain adjustments.

Bausch Health Agrees To Sell Amoun Pharmaceuticals

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Down 0.6% Since Last Earnings Report?

There are challenges to value creation in the proposed separation of Bausch Health Companies Inc's (NYSE: BHC) Bausch and Lomb (B&L) unit and RemainCo, which will be pharma-focused, according to BofA Securities. The Bausch Health Analyst: Jason Gerberry downgraded the rating for Bausch Health from Neutral to Underperform, while reducing the price target from $33 to $27.

News for Bausch Health Companies Inc Stock (BHC)